Scarica l'app Stockscreener
138.60
2.71%
3.66
Dopo l'orario di chiusura:
139.60
1.00
+0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Forsta AP Fonden - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by LPL Financial LLC - MarketBeat
Biogen’s New Clinical Trial: A Potential Game-Changer for Kidney Transplant Patients - TipRanks
Biogen’s Omaveloxolone Study: A New Hope for Young FA Patients - TipRanks
Biogen’s Litifilimab Study: A Long-Term Look at Lupus Treatment - TipRanks
E Fund Management Co. Ltd. Acquires 3,160 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mizuho Securities USA LLC Sells 2,091 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development - MSN
Deutsche Bank AG Cuts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
National Bank of Canada FI Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
White Lighthouse Investment Management Inc. Purchases New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wolfe Research Has Negative Forecast for Biogen Q4 Earnings - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Position Raised by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks
April 2026 Options Now Available For Biogen (BIIB) - Nasdaq
Piper Sandler raises Biogen stock price target to $118 on Alzheimer’s drug data By Investing.com - Investing.com South Africa
Stock Analysis | Biogen OutlookNavigating Mixed Signals and a Strong Fundamentals Picture - AInvest
AIA Group Ltd Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Dementia and Alzheimer's Disease Treatment Market To Witness - openPR.com
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Aigen Investment Management LP Invests $1.97 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of ... - Bluefield Daily Telegraph
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - TradingView
Why Is Biogen Stock Climbing Wednesday?Biogen (NASDAQ:BIIB) - Benzinga
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments - TipRanks
Rituxan Market Size to 2025: Emerging Demands, Trends, - openPR.com
Biogen Asserts No Obligation to Pay $122M in Intellectual Property Royalties Following Mistrial - USA Herald
5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call - Yahoo Finance
BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Motley Fool Asset Management LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Invesco Ltd. - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ontario Teachers Pension Plan Board Buys Shares of 10,849 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Says It Owes Nothing After $122M IP Royalties Mistrial - Law360
Sector Update: Health Care - MarketScreener
Biogen CEO Sees Potential in Combining Alzheimer's, Obesity Drugs - MarketScreener
Biogen CEO sees potential in combining Alzheimer's and obesity drugs, despite Novo's trial success. - AInvest
Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment? - TipRanks
Biogen Sees Potential in Combining Alzheimer’s and Obesity Drugs - Bloomberg.com
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Entropy Technologies LP - MarketBeat
Headlands Technologies LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment - TipRanks
Biogen Faces Growing Pains Even As Its Pipeline Progresses - Finimize
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com Australia
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Biogen
Breakthrough Dravet Syndrome Drug Could Transform Treatment: Phase 3 Trial Launches - Stock Titan
Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN
1.49%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):